Pfizer Kick Starts Late-Stage Study For COVID-19 Oral Antiviral For Post-Exposure Prophylaxis
Pfizer Inc (NYSE: PFE) has started the Phase 2/3 EPIC-PEP study to evaluate its oral antiviral candidate PF-07321332, co-administered with a low dose of ritonavir, for the prevention of COVID-19 infection.
Related: COVID-19 Oral Antiviral Drug From Pfizer Could Be Available By 2021, Says CEO: CNBC.
This Phase 2/3 trial is part of a global program and enrolls adult individuals who live in the same household as individuals with a confirmed symptomatic SARS-CoV-2 infection.
The Phase 2/3 EPIC-PEP trial will enroll up to 2,660 healthy adult participants aged 18 and older.
Participants will be randomly assigned to receive PF-07321332/ritonavir or placebo orally twice daily for 5 or 10 days.
The primary objective will assess safety and efficacy to prevent confirmed SARS-CoV-2 infection and its symptoms through Day 14.
In addition to this study, the global EPIC program consists of multiple ongoing trials, including one in SARS-CoV-2 infected patients at high risk of severe illness (including hospitalization or death), which began in July 2021.
Another trial is in infected patients at standard risk (i.e., do not have risk factors for severe illness), which began in August 2021.
Price Action: PFE stock is down 0.30% at $43.81 during the market session on the last check Monday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
